To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Kristie L. Kahl
Patients going through cancer treatment may be susceptible to oral mucositis (mouth sores), which can make simple tasks such as eating, talking, or breathing very painful, but a new intraoral ice pack can help combat just that.
Katie Kosko
A person’s pre-existing mental state may negatively influence their health, but professional support can help maintain the best mindset, say researchers.
Beth Fand Incollingo
Menopausal women who take hormonal therapy after surgery for breast cancer may be prone to long-term “chemo brain” – potentially benefitting from cognitive therapy or other interventions.
Kristie L. Kahl
Because of the rarity of a neuroendocrine tumor (NET) diagnosis, the Healing Net Foundation aims to educate physicians on the disease – an initiative many patient advocates feel can improve outcomes.
Jessica Skarzynski
A new analysis of the myMPN Patient Registry has led to some exciting new discoveries, according to researchers.

Susan G. Komen Greater New York City
Although Minority Health Awareness Month is drawing to an end, the fight for equity in healthcare isn’t over.
Beth Fand Incollingo
Evaluations can identify the potential for drug interactions and predict whether older patients are fit for chemotherapy.
Gina Columbus
The Food and Drug Administration approved Keytruda in combination with Inlyta for the frontline treatment of patients with advanced renal cell carcinoma.
Alexandra Guadagno
From Testicular Cancer Awareness Month to a superhero-themed fundraiser, here’s what’s making headlines in the cancer space this week.
Katie Kosko
Researchers examine genomic mutations with tumor response to Keytruda and Opdivo in patients with GBM, highlighting the potential for a molecular, personalized approach to treat certain patients.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other